Literature DB >> 29079708

miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

Yuanzheng Yang1, Gangxiong Huang1,2, Zhichao Zhou1, Jason G Fewell3, Eugenie S Kleinerman4.   

Abstract

The metastatic potential of osteosarcoma cells is inversely correlated to cell surface FAS expression. Downregulation of FAS allows osteosarcoma cells to escape FAS ligand-mediated apoptosis when they enter a FAS ligand-positive microenvironment such as the lung. We have previously demonstrated that miR-20a, encoded by the miR-17-92 cluster, downregulates FAS expression in osteosarcoma. We further demonstrated an inverse correlation between FAS expression and miR-20a expression. However, the mechanism of FAS regulation by miR-20a was still unclear. The purpose of the current study was to evaluate the mechanism of FAS regulation by miR-20a in vitro and test the effect of targeting miR-20a in vivo We investigated whether miR-20a's downregulation of FAS was mediated by binding to the 3'-untranslated region (3'-UTR) of FAS mRNA with the consequent induction of mRNA degradation or translational suppression. We identified and mutated two miR-20a binding sites on the FAS mRNA 3'-UTR. Using luciferase reporter assays, we demonstrated that miR-20a did not bind to either the wild-type or mutated FAS 3'-UTR. In contrast, overexpression of miR-20a resulted in downregulation of FAS promoter activity. Similarly, the inhibition of miR-20a increased FAS promoter activity. The critical region identified on the FAS promoter was between -240 bp and -150 bp. Delivery of anti-miR-20a in vivo using nanoparticles in mice with established osteosarcoma lung metastases resulted in upregulation of FAS and tumor growth inhibition. Taken together, our data suggest that miR-20a regulates FAS expression through the modulation of the FAS promoter and that targeting miR-20a using anti-miR-20a has therapeutic potential. Mol Cancer Ther; 17(1); 130-9. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29079708      PMCID: PMC5752589          DOI: 10.1158/1535-7163.MCT-17-0042

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  52 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 2.  Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis.

Authors:  Mattia Boeri; Ugo Pastorino; Gabriella Sozzi
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

3.  Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.

Authors:  Nancy Gordon; Nadezhda V Koshkina; Shu-Fang Jia; Chand Khanna; Arnulfo Mendoza; Laura L Worth; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

4.  Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.

Authors:  Jared M McLendon; Sachindra R Joshi; Jeff Sparks; Majed Matar; Jason G Fewell; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry; William T Gerthoffer
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

5.  Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.

Authors:  Nadezhda V Koshkina; Eugenie S Kleinerman
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

6.  Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.

Authors:  Elizabeth A Lafleur; Nadezhda V Koshkina; John Stewart; Shu-Fang Jia; Laura L Worth; Xiaoping Duan; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

7.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

8.  Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.

Authors:  Nadezhda V Koshkina; Chand Khanna; Arnulfo Mendoza; Hui Guan; Lindsey DeLauter; Eugenie S Kleinerman
Journal:  Mol Cancer Res       Date:  2007-10       Impact factor: 5.852

9.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

10.  MicroRNA Involvement in Osteosarcoma.

Authors:  Eisuke Kobayashi; Francis J Hornicek; Zhenfeng Duan
Journal:  Sarcoma       Date:  2012-04-03
View more
  6 in total

Review 1.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

2.  Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.

Authors:  Luciana M Gutiérrez; Matías Valenzuela Alvarez; Yuanzheng Yang; Fiorella Spinelli; María José Cantero; Laura Alaniz; Mariana G García; Eugenie S Kleinerman; Alejandro Correa; Marcela F Bolontrade
Journal:  Apoptosis       Date:  2021-05-22       Impact factor: 4.677

3.  MiR-20a, a novel promising biomarker to predict prognosis in human cancer: a meta-analysis.

Authors:  Donghua Huang; Yizhong Peng; Kaige Ma; Xiangyu Deng; Lu Tang; Doudou Jing; Zengwu Shao
Journal:  BMC Cancer       Date:  2018-11-29       Impact factor: 4.430

4.  The miR-204-5p/FOXC1/GDF7 axis regulates the osteogenic differentiation of human adipose-derived stem cells via the AKT and p38 signalling pathways.

Authors:  You Zhou; Siyu Liu; Wei Wang; Qiang Sun; Mengzhu Lv; Shude Yang; Shuang Tong; Shu Guo
Journal:  Stem Cell Res Ther       Date:  2021-01-18       Impact factor: 6.832

Review 5.  miR-aculous new avenues for cancer immunotherapy.

Authors:  William W Tang; Kaylyn M Bauer; Cindy Barba; Huseyin Atakan Ekiz; Ryan M O'Connell
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

6.  Identification of Novel Target for Osteosarcoma by Network Analysis.

Authors:  Li-Qiang Zhi; Yi-Xin Yang; Shu-Xin Yao; Zhong Qing; Jian-Bing Ma
Journal:  Med Sci Monit       Date:  2018-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.